Company Overview and News
Late Friday last week, little known Pinehill Pacific Bhd (formerly known as Multi Vest Resources Bhd, which by the way was formerly known as Best World Land Bhd) surprised the market with the announcement that it was parting with nearly 9,000 acres of landbank and related plantation assets held via three subsidiary companies to United Plantations Bhd (UP) for a whopping sum of RM413.6mil.
2038 5138 1996 UPBMF 4383 7501 1902 2089 5112
High demand: Among the suitors eyeing IJM Plantations, which has 61,000ha of planted area in Sabah, Kalimantan and Sumatra, are plantation groups such as IOI and Hap Seng Plantations.
5138 1996 2216 5254
In the hey days of the market in the 1990s, public viewing galleries will cheer every time when they see Kretam Holdings Bhd ’s (Kretam) share price move along with other market darlings of the yesteryear. They would say in the Malay language, “Ketam mari, Ketam mari”, as in the stock is having an upward run and it’s time to “jump in.”
KUALA LUMPUR (June 22): The FBM KLCI fell 0.66% at mid-morning today, tracking losses at the regional markets as investor sentiment remained jittery given the spectre of a global trade war.
APEXF 7090 UPBMF 4065 7235 BATS 4162 2089 9334 KLKBY 2445 4863 5347 1996 0026 TNABY MYTEF 2836 TNABF MGFCF
Hap Seng Plantations Holdings Bhd (June 19, RM2.21) Upgrade to market perform with a higher target price (TP) of RM2.15: Hap Seng Plantations Holdings Bhd announced that it had terminated its share sale agreement to acquire 55% of Kretam Holdings Bhd from Datuk Lim Nyuk Sang @ Freddie Lim and Santaprise Sdn Bhd after finalising its due diligence process and finding the results “unsatisfactory and unacceptable”.
KUALA LUMPUR (June 19): The FBM KLCI extended its loss at the midday break today and dropped 0.65%, dragged by banking heavyweights Public Bank Bhd and Malayan Banking Bhd (Maybank).
HLFBF APEXF PBLOF 7090 MLYNF 7113 4065 TPGVF 1295 2852 3026 3301 2836 MLYBY 1082 5681 0096 5202 7123 TGLVY 1155 4588 1996 0026 3719
KUALA LUMPUR (June 19): The FBM KLCI was down 0.42% at mid-morning today, in line with the pullback at most regional markets as the tariff tit-for-tat between the US and China intensified.
HLFBF APEXF 7090 5150 4065 1082 5681 BATS 4162 5014 7123 3026 3867 1996 0026 MYPRY 3719
KUALA LUMPUR: Kretam Holdings Bhd’s share price yesterday sank to its lowest since September 2015 with some half a billion ringgit worth of market capitalisation wiped out in a day, after Hap Seng Plantations Holdings Bhd called off a plan to take up a controlling 55% stake in the company.
KUALA LUMPUR (June 18): The FBM KLCI fell 18.35 points or 1.04%, tracking Asian share losses as investors evaluated the impact of the US-China trade spat on world markets.
KLKBY 2445 1996 5681 BSMAF 1818
KUALA LUMPUR (June 18): The FBM KLCI pared some of its losses at the midday break and was down 0.78%, with tepid sentiment tracking losses at the regional markets.
APEXF 7251 7090 7113 BATS TPGVF 4162 3034 KLKBY 5226 5347 3301 TNABY AXXTF HRGHY 5681 2291 1163 5168 TGLVY 2445 1996 6888 5819 TNABF
Hap Seng Consolidated Bhd (+ve) TRADING of the shares in Hap Seng Consolidated Bhd (fundamental: 1.3/3, valuation: 1.3/3) triggered our momentum algorithm last Thursday for the first time this year. The group saw 937,700 shares traded.
5138 1996 3034
KUALA LUMPUR (June 18): Kretam Holdings Bhd's stock price nosedived in early trade today to its lowest since September 2015, after its plans to sell a 55% stake to Hap Seng Plantations Holdings Bhd had been called off.
5138 1996 BSMAF 1818
The possible announcement of the full Cabinet line-up could be among the highlights this week, even as businesses continue to cash in on the World Cup 2018 fever and the zero-rated Goods and Services Tax (GST) “tax holiday”. There was no Cabinet meeting last Wednesday (June 13) with Prime Minister Tun Dr Mahathir Mohamad just returning from a work trip in Japan (June 11 and 12) and Hari Raya Puasa festivities on June 15 and 16.
8591 5139 9571 5797 1996 0900 5263 5098 0065 5156
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to MYX:1996 / KRETAM HOLDINGS BERHAD on message board site Silicon Investor.
|IDID GO!GO! MAY 28,1996||IDID GO!GO! MAY 28,1996||IDID GO!GO! MAY 28,1996||TAX SELLING PICKS FOR 1996 97||TAX SELLING PICKS FOR 1996 97||TAX SELLING PICKS FOR 1996 97|